Frontline nilotinib supported for newly diagnosed CP–CML

Long-term results from the ENESTnd trial indicate a favourable risk–benefit profile for frontline use of nilotinib in patients within 6 months of chronic phase–chronic myeloid leukaemia diagnosis.
Source: MedWire News - Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news